Skip to main content
TipRanks
Go Ultimate75% OFF

DENTSPLY SIRONA (DY2) Q3 2026 Earnings Report

2 Followers

DE:DY2 Q3 2026 EPS Results

Actual EPS
EUR 0.26
Consensus EPS
EUR 0.28
Beat/Miss
Missed by -EUR 0.02
One Year Ago EPS
EUR 0.34

DE:DY2 Q3 2026 Revenue Results

Actual Revenue
EUR 758.38M
Expected Revenue
EUR 781.68M
Beat/Miss
Missed by -EUR 23.30M
YoY Revenue Growth
-7.52%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
After Close
Conference Call
Thursday, November 5, 2026
DE:DY2 Upcoming Earnings

DENTSPLY SIRONA's next earnings date is estimated for March 4, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:DY2 Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:-11.44%|
Earnings Call Sentiment|Neutral

The call was mixed but leaned positive on operational progress. The company reported significant momentum at Wellspect and in selected U.S. businesses, along with stronger commercial coverage, increased clinical education, product approvals, and cost-saving initiatives. However, these developments were outweighed in the near term by a 7.6% reported revenue decline, lower adjusted EPS, reduced full-year guidance, weaker cash flow, and continued pressure across several dental segments and international markets.

Company Guidance

For 2026, DENTSPLY SIRONA now expects full-year net sales of approximately $3.5 billion, versus the previous range of $3.5 billion-$3.6 billion, and adjusted EPS of $1.20-$1.30, versus $1.40-$1.50, excluding the $0.17 one-time gain from tariff refunds; the $39 million pre-tax, $30 million post-tax inventory benefit is included in guidance. Management said the Q4 outlook is “fairly doable” with “certain upticks” in some markets and “a little bit of” mix shift, and Dan said he is “looking for even a 0.1 or a 0.2” in the U.S. and retains the “aspiration of getting a plus sign by the fourth quarter,” while noting it is “a stretch”; the company is advancing an approximately $120 million 2026 savings initiative, and management is “not giving 2027 guidance.”

  • Progress on Return-to-Growth Action PlanDENTSPLY SIRONA expanded customer access, strengthened its commercial organization, and increased investment in clinical education and innovation during the third quarter. Management said it is seeing early gains in parts of the U.S. dental business and is focused on converting them into broader, sustained improvement.
  • Wellspect Delivered Record GrowthWellspect Healthcare reported record quarterly sales and double-digit revenue growth, with revenue increasing 10% to $92 million as reported. Growth was driven by higher volumes and strong new product sales, particularly Surity in the U.S. Management said Wellspect has delivered consistent growth throughout 2026.
  • U.S. MIS and Value Implant MomentumU.S. MIS sales grew at a low double-digit rate in the third quarter, while overall value implant sales increased more than 7% year-over-year. Customer conversions accelerated sharply in September, and management plans to nearly double the MIS sales force by year-end.
  • U.S. Endodontics Returned to GrowthU.S. Endo sales increased 4% in the quarter, returning to growth for the first time since Q2 2025. Management attributed early momentum to clinical education, product strength, and commercial execution.
  • Improved Commercial Coverage and HiringQuota-carrying field vacancies in the U.S. declined to the mid-single digits from more than 20% in prior years. Management also reported significantly improved recruitment and retention, substantially lower voluntary sales representative attrition, completed certification for all premium implant representatives, and expected MIS certification by the end of the month.
  • Expansion of Dealer and Enterprise ChannelsThe company signed seven new distribution agreements year-to-date and said its North American dealer expansion efforts are largely complete. It is now focused on activating the network through training, joint customer visits, demonstrations, and installation support. DENTSPLY also built out a new team focused on expanding relationships with dental service organizations.
  • Significant Clinical Education InvestmentSecond-half 2026 clinical education investment in North America is six times greater than last year's level, including more than 160 Endo courses and expanded hands-on programs. Across global DS World events, workshops, lectures, and hands-on continuing education courses increased by more than 60% versus last year.
  • Increased R&D and Product Development ActivityR&D spending increased approximately 20% through September compared with last year. The company established a new product development process with customer-informed requirements, stage-gate reviews, and earlier planning for training and clinical education.
  • New Product and Regulatory MilestonesDENTSPLY introduced Primescan Connect, powered by DS Core, as a more affordable scanner option. The company also received U.S. and Canadian approval for OSSIX Plus and Canadian approval for OSSIX Volumax, with U.S. clearance for OSSIX Volumax expected soon.
  • Preventive, EMEA Ortho, and Selected Segment StrengthPreventive revenue grew double digits in EMEA and APAC. SureSmile revenue in EMEA increased 8%, marking the region's sixth quarter of mid-single-digit or better year-over-year growth in seven quarters. Instruments grew low single digits, supported by U.S. momentum through the ADAC partnership and 4% growth in Intego handpieces in EMEA.
  • Gross Margin Improvement and Cost ActionsAdjusted gross margin improved 190 basis points year-over-year. Cost management initiatives and favorable manufacturing absorption partially offset lower dental volumes and higher distribution costs. The transformation office is advancing an approximately $120 million 2026 savings initiative.
  • Share Repurchases and Capital AllocationThe company repurchased 1.2 million shares in the third quarter and has returned $25 million to shareholders through repurchases year-to-date. Management said debt reduction remains a core tenet of its capital allocation strategy.
  • Wellspect Medicare Coverage ExpansionThe Wellspect Surity portfolio recently qualified for traditional Medicare coverage, expanding access to at-home care for eligible patients. Wellspect's investments increased 15% year-over-year as it pursues the $7 billion urinary management market.
  • Proposed Byte Litigation Settlement Covered by InsuranceThe company entered into a memorandum of understanding for a proposed settlement of the 2024 Byte securities litigation. Management stated that the proposed settlement amount will be covered by liability insurance policies.

DE:DY2 Earnings History

DE:DY2 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 04, 20272026 (Q4)0.30-0.24――
Nov 05, 20262026 (Q3)0.280.260.34-21.62% (-0.07)
Aug 06, 20262026 (Q2)0.320.470.470.00% (+0.00)
May 05, 20262026 (Q1)0.250.240.39-37.21% (-0.15)
Feb 26, 20262025 (Q4)0.250.240.243.85% (+0.01)
Nov 06, 20252025 (Q3)0.410.340.45-26.00% (-0.12)
Aug 07, 20252025 (Q2)0.460.470.446.12% (+0.03)
May 08, 20252025 (Q1)0.270.390.382.38% (+0.01)
Feb 27, 20252024 (Q4)0.390.240.4-40.91% (-0.16)
Nov 07, 20242024 (Q3)0.430.450.442.04% (+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed